Marika J. Hohol
Brigham and Women's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marika J. Hohol.
Multiple Sclerosis Journal | 1999
Marika J. Hohol; E. J. Orav; Howard L. Weiner
Clinical assessment of outcome in Multiple Sclerosis (MS) patients is problematic since the disease can affect different aspects of the central nervous system and follow a variable course. Recently, we developed Disease Steps, a simple approach for evaluating disease progression. Previously, we found that Disease Steps was easy to use, had uniformly distributed scores and low inter-rater variability. Our current objective was to test the long-term use of Disease Steps together with the most widely utilized clinical outcome measure in MS, the Expanded Disability Status Scale (EDSS) in assessing clinical progression. Over 4 years, 804 patients were classified using both EDSS and Disease Steps. Each patient was assessed at least twice. Follow-up results included annual status and time-to-event analysis examining median staying times within a level of Disease Steps or EDSS. We found that the two scales behaved similarly and correlated strongly with each other. For both Disease Steps and EDSS, patients with milder levels of disability and relapsing-remitting disease demonstrated a higher likelihood of changing scores over time and shorter median staying times compared to more disabled, chronic progressive patients. These findings have important implications for patient selection in clinical trials and for the design of future measurements of clinical outcome in MS. Furthermore, Disease Steps may serve as a simple, practical tool for the nonspecialty neurologist to follow patients over time and serve as a guide in therapeutic decision making. Our findings further document the general progressive nature of MS when a large cohort is followed in an MS specialty clinic over time.
Neurology | 1994
Samia J. Khoury; Charles R. G. Guttmann; E. J. Orav; Marika J. Hohol; Sungkee S. Ahn; Li Hsu; Ron Kikinis; Glenn A. Mackin; Ferenc A. Jolesz; Howard L. Weiner
We followed 18 multiple sclerosis patients clinically and with repeated brain MRIs with and without gadolinium for over 1 year. Clinical evaluations included scoring on the Kurtzke Expanded Disability Status Scale (EDSS) and the Ambulation Index (AI) scale. There was a significant correlation between the change in EDSS or AI and the change in number of lesions on MRI and between cumulative number of lesions on MRI and cumulative change in EDSS or AI. Our findings support the validity of MRI as a measure of clinical activity and potentially as an objective quantitative outcome measure for assessing response to therapy.
Journal of Neuroimmunology | 2000
Howard L. Weiner; Charles R. G. Guttmann; Samia J. Khoury; E. John Orav; Marika J. Hohol; Ron Kikinis; Ferenc A. Jolesz
Serial MRI and clinical testing was performed on 45 well-defined untreated multiple sclerosis patients in different categories of disease (relapsing-remitting, progressive, stable). Up to 24 MRIs were scheduled over a 1-year period for each patient. Clinical evaluation was performed monthly and at times of attacks using the Expanded Disability Status Scale (EDSS) and the Ambulation Index (AI). MRI scans were performed both with and without gadolinium enhancement. MRI lesion volume was determined by computerized analysis and gadolinium-enhancing lesions were counted by radiologists. We observed an increase in lesion volume over 1 year in all patient groups except those classified clinically as stable. In relapsing-remitting patients there were correlations between increases in the number of gadolinium enhancing lesions and increases in EDSS and the occurrence of attacks. In chronic progressive patients, increases in lesion volume were correlated with both increases in EDSS and AI. These results demonstrate a linkage between MRI and clinical disease that depends both on the stage of MS and the MRI measures used and support the use of MRI as a surrogate marker of clinical disability in the study of multiple sclerosis.
Multiple Sclerosis Journal | 1999
Marika J. Hohol; Michael J. Olek; E. John Orav; Lynn Stazzone; David A. Hafler; Samia J. Khoury; David M. Dawson; Howard L. Weiner
Objective: To determine if there are variables linked to responsiveness to pulse cyclophosphamide/methylprednisolone therapy in progressive Multiple Scerosis (MS). Background: MS is a presumed autoimmune disease of the CNS in which immunosuppressive and immunomodulatory treatments are being used. We have treated patient with the progressive form of MS using a regimen consisting of pulse cyclophosphamide/methylprednisolone that is given as an outpatient at 4-8 week intervals similar to lupus nephritis protocols. Design/Methods: We investigated a series of 95 consecutive progressive MS patient treated in an open label fashion in an effort to identify factors linked to response to treatment. Clinical outcome measures included status at 12 months and time to failure determined by EDSS change and global physician impression. For each endpoint associations were examined between outcome and patient characteristics including gender age at onset of disease and treatment, EDSS 1 year previously and at start of treatment, duration of MS, previous treatment, age at onset and duration of progression, and primary vs secondary progressive MS. Result: Of the variables studied, age, gender, age at onset, and age at treatment did not correlate with response to therapy. The most significant variable that correlated with response was length of time the patient was in the progressive phase (P=0.048, 12 month change in EDSS; P=0.017, risk for time to failure). Patient that improved on therapy at 12 months had progressive disease for an average of 2.1 years prior to treatment, whereas those stable or worse had progressive disease for 5.0 and 4.1 years respectively. There was a trend (P=0.08) favoring positive clinical responses in secondary progressive as opposed to primary progressive patients. Conclusions: Our data suggest that progressive MS may become refractory to immunosuppressive therapy with time and early intervention when patient enter the progressive stage should be considered. Furthermore, in trials of immunosuppressive agent for progressive MS, duration of progression should be considered as a randomization and analysis variable.
Neurology | 1995
Howard L. Weiner; C. R.G. Guttman; Samia J. Khoury; Marika J. Hohol; D. A. Hafler; E. J. Orav; Li Hsu; Sungkee S. Ahn; Ron Kikinis; Ferenc A. Jolesz
‘ “Works in Progress” is a feature of the Scientific Program of the American Academy of Neurology Annual Meeting. It focuses on current ongoing neuroscience research. Works i n Progress posters are selected on the basis of scientific merit, timeliness, and anticipated interest to the membership. Key aspects of the research had to have been conducted afcer October 11, 1994, and had to have been currently in progress. The posters were displayed during the Scientific Program a t this year’s annual meeting and are reproduced here i n abstract form.
JAMA Neurology | 2001
Reisa A. Sperling; Charles R. G. Guttmann; Marika J. Hohol; Simon K. Warfield; Marianna Jakab; Marco Parente; Eli L. Diamond; Kirk R. Daffner; Michael J. Olek; E. John Orav; Ron Kikinis; Ferenc A. Jolesz; Howard L. Weiner
JAMA Neurology | 1997
Marika J. Hohol; Charles R. G. Guttmann; John Orav; Glenn A. Mackin; Ron Kikinis; Samia J. Khoury; Ferenc A. Jolesz; Howard L. Weiner
Archive | 2015
Reisa A. Sperling; Charles R. G. Guttmann; Marika J. Hohol; Simon K. Warfield; Marianna Jakab; Marco Parente; Eli L. Diamond; Kirk R. Daffner; Michael J. Olek; E. John Orav; Ron Kikinis; Ferenc A. Jolesz; Howard L. Weiner
Annals of the New York Academy of Sciences | 1996
Marika J. Hohol; Samia J. Khoury; Sandra Cook; E. John Orav; David A. Hafler; Howard L. Weiner
Neurologic Clinics | 1995
Howard L. Weiner; Marika J. Hohol; Samia J. Khoury; David M. Dawson; David A. Hafler